98 related articles for article (PubMed ID: 13129582)
1. Conformational and SAR analysis of NAALADase and PSMA inhibitors.
Oliver AJ; Wiest O; Helquist P; Miller MJ; Tenniswood M
Bioorg Med Chem; 2003 Oct; 11(20):4455-61. PubMed ID: 13129582
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M
J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationship studies of prostate-specific membrane antigen (PSMA) inhibitors derived from α-amino acid with (S)- or (R)-configuration at P1' region.
Kwon H; Lim H; Ha H; Choi D; Son SH; Nam H; Minn I; Byun Y
Bioorg Chem; 2020 Nov; 104():104304. PubMed ID: 33011530
[TBL] [Abstract][Full Text] [Related]
4. Looking for Drugs in All the Wrong Places: Use of GCPII Inhibitors Outside the Brain.
Vornov JJ; Peters D; Nedelcovych M; Hollinger K; Rais R; Slusher BS
Neurochem Res; 2020 Jun; 45(6):1256-1267. PubMed ID: 31749072
[TBL] [Abstract][Full Text] [Related]
5. Novel β- and γ-Amino Acid-Derived Inhibitors of Prostate-Specific Membrane Antigen.
Kim K; Kwon H; Barinka C; Motlova L; Nam S; Choi D; Ha H; Nam H; Son SH; Minn I; Pomper MG; Yang X; Kutil Z; Byun Y
J Med Chem; 2020 Mar; 63(6):3261-3273. PubMed ID: 32097010
[TBL] [Abstract][Full Text] [Related]
6. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
Hillier SM; Maresca KP; Lu G; Merkin RD; Marquis JC; Zimmerman CN; Eckelman WC; Joyal JL; Babich JW
J Nucl Med; 2013 Aug; 54(8):1369-76. PubMed ID: 23733925
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of PSMA/hepsin-targeted heterobivalent ligands.
Subedi M; Minn I; Chen J; Kim Y; Ok K; Jung YW; Pomper MG; Byun Y
Eur J Med Chem; 2016 Aug; 118():208-218. PubMed ID: 27128184
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
Umbricht CA; Benešová M; Schibli R; Müller C
Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
[TBL] [Abstract][Full Text] [Related]
9. A high-affinity [(18)F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer.
Ganguly T; Dannoon S; Hopkins MR; Murphy S; Cahaya H; Blecha JE; Jivan S; Drake CR; Barinka C; Jones EF; VanBrocklin HF; Berkman CE
Nucl Med Biol; 2015 Oct; 42(10):780-7. PubMed ID: 26169882
[TBL] [Abstract][Full Text] [Related]
10. Cell-Surface labeling and internalization by a fluorescent inhibitor of prostate-specific membrane antigen.
Liu T; Wu LY; Kazak M; Berkman CE
Prostate; 2008 Jun; 68(9):955-64. PubMed ID: 18361407
[TBL] [Abstract][Full Text] [Related]
11. Syntheses of conformationally constricted molecules as potential NAALADase/PSMA inhibitors.
Ding P; Miller MJ; Chen Y; Helquist P; Oliver AJ; Wiest O
Org Lett; 2004 May; 6(11):1805-8. PubMed ID: 15151419
[TBL] [Abstract][Full Text] [Related]
12. Molecular characterization of human brain N-acetylated alpha-linked acidic dipeptidase (NAALADase).
Luthi-Carter R; Barczak AK; Speno H; Coyle JT
J Pharmacol Exp Ther; 1998 Aug; 286(2):1020-5. PubMed ID: 9694964
[TBL] [Abstract][Full Text] [Related]
13. Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors.
Benešová M; Bauder-Wüst U; Schäfer M; Klika KD; Mier W; Haberkorn U; Kopka K; Eder M
J Med Chem; 2016 Mar; 59(5):1761-75. PubMed ID: 26878194
[TBL] [Abstract][Full Text] [Related]
14. Rational design of urea-based glutamate carboxypeptidase II (GCPII) inhibitors as versatile tools for specific drug targeting and delivery.
Tykvart J; Schimer J; Bařinková J; Pachl P; Poštová-Slavětínská L; Majer P; Konvalinka J; Šácha P
Bioorg Med Chem; 2014 Aug; 22(15):4099-108. PubMed ID: 24954515
[TBL] [Abstract][Full Text] [Related]
15. Structure-Activity Relationship of (18)F-Labeled Phosphoramidate Peptidomimetic Prostate-Specific Membrane Antigen (PSMA)-Targeted Inhibitor Analogues for PET Imaging of Prostate Cancer.
Dannoon S; Ganguly T; Cahaya H; Geruntho JJ; Galliher MS; Beyer SK; Choy CJ; Hopkins MR; Regan M; Blecha JE; Skultetyova L; Drake CR; Jivan S; Barinka C; Jones EF; Berkman CE; VanBrocklin HF
J Med Chem; 2016 Jun; 59(12):5684-94. PubMed ID: 27228467
[TBL] [Abstract][Full Text] [Related]
16. Molar Activity of Ga-68 Labeled PSMA Inhibitor Conjugates Determines PET Imaging Results.
Wurzer A; Pollmann J; Schmidt A; Reich D; Wester HJ; Notni J
Mol Pharm; 2018 Sep; 15(9):4296-4302. PubMed ID: 30011372
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents.
Kozikowski AP; Zhang J; Nan F; Petukhov PA; Grajkowska E; Wroblewski JT; Yamamoto T; Bzdega T; Wroblewska B; Neale JH
J Med Chem; 2004 Mar; 47(7):1729-38. PubMed ID: 15027864
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of a siderophore conjugate as a potent PSMA inhibitor and potential diagnostic agent for prostate cancer.
Ding P; Helquist P; Miller MJ
Bioorg Med Chem; 2008 Feb; 16(4):1648-57. PubMed ID: 18060794
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and pre-clinical evaluation of a new class of high-affinity
Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity relationships of 2',5'-oligoadenylate analogue modifications of prostate-specific membrane antigen (PSMA) antagonists.
Wang X; Tian H; Lee Z; Heston WD
Nucleosides Nucleotides Nucleic Acids; 2012 May; 31(5):432-44. PubMed ID: 22497258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
